Question 1

Am I eligible for this trial based on my current condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) clinical trial (NCT04778800). Contact the study team or your healthcare provider for specific answers.

Question 2

How does almonertinib compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) clinical trial (NCT04778800). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of almonertinib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) clinical trial (NCT04778800). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for evaluations and treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) clinical trial (NCT04778800). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my condition worsens while I am in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) clinical trial (NCT04778800). Contact the study team or your healthcare provider for specific answers.

Question 6

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY) clinical trial (NCT04778800). Contact the study team or your healthcare provider for specific answers.

What this study is about